IgAN Treatment Patterns in 2026: Real-World Insights from 2,100 Patient Charts Across the United States, the Five Major European Markets (EU5), and China (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0476; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Targeted budesonide, sparsentan, and/or atrasentan are used in earlier lines and in patients with lower disease severity, while agents such as iptacopan and sibeprenlimab are reserved for patients with more advanced or progressive disease. While foundational therapies remain the standard of care, targeted agents are being incorporated based on disease severity and progression. Ongoing gaps in disease control highlight the need for additional treatment options."
Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Renal Disease
|
|
Jennifer Lafave; Stephanie Tomazin; Kari McCarthy
|